Skip to main content

Sign up for our newsletter.

Quality journalism. Progressive values. Direct to your inbox.

ONE DAY left in this Mid-Year Campaign. This is our hour of need.
If you value independent journalism, please support Common Dreams.

Join the small group of generous readers who donate, keeping Common Dreams free for millions of people each year. Without your help, we won’t survive.

The Gilead Sciences logo is seen on the company website. (Photo: Ivan Radic/Flickr/cc)

'Big Win': Caving to Pressure Campaign, Gilead Sciences Relinquishes Monopoly Claim for Promising Coronavirus Treatment

"There's no doubt that the prospect of an enormous public backlash is what made the difference."

Julia Conley

Government watchdog Public Citizen celebrated Wednesday afternoon as pharmaceutical giant Gilead Sciences backed off a monopoly claim for its drug that may treat the coronavirus which has sickened more than 487,000 people worldwide. Gilead, Public Citizen said, must now commit to ensuring the drug is accessible to all who need it.

Public Citizen applauded the news as a "big win" for those who spoke out against Gilead Sciences, whose former lobbyist, Joe Grogan, now serves on President Donald Trump's so-called "coronavirus task force."

"It was outrageous that Gilead ever sought an 'orphan drug' designation for remdesivir, which aims to treat a patient population that easily may number in the tens of millions in the U.S. alone," Peter Maybarduk, director of Public Citizen's Access to Medicines program, said in a statement. "Thankfully, under pressure, the company has backed down. There's no doubt that the prospect of an enormous public backlash is what made the difference."

Gilead's claim to "orphan" drug status for remdesivir, one of several drugs being tested to treat the coronavirus, officially known as COVID-19, drew outrage this week from Public Citizen, Sen. Bernie Sanders (I-Vt.), and dozens of other public interest advocates. 

Trump's Food and Drug Administration granted the orphan status—which would allow a seven-year monopoly on the drug and could keep it out of reach of many Americans by preventing other companies from developing generic versions—even though Gilead developed remdesivir with at least $79 million in government funds. Orphan status is generally reserved for companies that may not recoup their research costs and for drugs which treat conditions affecting fewer than 200,000 people.

"Gilead must have been feeling the heat," James Love, director of public interest non-profit Knowledge Ecology International, told NPR after Gilead reliquished its claim. "I think it's embarrassing to take something that's potentially the most widespread disease in the history of the pharmaceutical industry and claim it's a rare disease."

Soon after Public Citizen was joined by 50 other groups in demanding Gilead end its "unconscionable abuse of a program designed to incentivize research and development of treatments for rare diseases," the company announced on Wednesday it would proceed without orphan drug status. 

Public Citizen said that Gilead Sciences must go further than simply withdrawing its claim of orphan drug status, and actively work to ensure that remdesivir is widely produced and available for all who need it.

"Gilead must do more than make vague promises of reasonable pricing," Maybarduk said. "It should commit right now to license the right and needed know-how to manufacture remdesivir to all qualified producers, in exchange for a modest royalty."

"If the drug proves viable as a COVID-19 treatment," he added, "the U.S. and the world will need the product available at a low price that reflects both the public health need and the potentially enormous market—with production at an unprecedented scale." 


Our work is licensed under Creative Commons (CC BY-NC-ND 3.0). Feel free to republish and share widely.

Just ONE DAY left in our crucial Mid-Year Campaign and we might not make it without your help.
Who funds our independent journalism? Readers like you who believe in our mission: To inform. To inspire. To ignite change for the common good. No corporate advertisers. No billionaire founder. Our non-partisan, nonprofit media model has only one source of revenue: The people who read and value this work and our mission. That's it.
And the model is simple: If everyone just gives whatever amount they can afford and think is reasonable—$3, $9, $29, or more—we can continue. If not enough do, we go dark.

All the small gifts add up to something otherwise impossible. Please join us today. Donate to Common Dreams. This is crunch time. We need you now.

As US Rolls Back Reproductive Rights, Sierra Leone Moves to Decriminalize Abortion

"I'm hopeful today's announcement gives activists in the U.S., and especially Black women given the shared history, a restored faith that change is possible and progress can be made."

Brett Wilkins ·


'Indefensible': Outrage as New Reporting Shines Light on Biden Deal With McConnell

The president has reportedly agreed to nominate an anti-abortion Republican to a lifetime judgeship. In exchange, McConnell has vowed to stop blocking two Biden picks for term-limited U.S. attorney posts.

Jake Johnson ·


Assange Makes Final Appeal Against US Extradition

"If Julian Assange is not free, neither are we," said a protester at a Friday demonstration against the WikiLeaks founder's impending transfer. "None of us is free."

Brett Wilkins ·


'Payoff for 40 Years of Dark Money': Supreme Court Delivers for Corporate America

"It was the conservative court's larger agenda to gut the regulatory state and decimate executive powers to protect Americans' health and safety," warned one expert.

Jake Johnson ·


NARAL Pro-Choice Endorses Fetterman—Who Vows to End Senate Filibuster to Protect Abortion Rights

"We know we can count on him to boldly fight for abortion rights and access," said the head of one of the nation's largest reproductive rights advocacy groups.

Jon Queally ·

Common Dreams Logo